Newly approved drugs to lower cholesterol are priced much too high, according to the Institute for Clinical and Economic Review, an outside nonprofit which monitors cost and care issues. The companies that make the new drugs question the nonprofit’s methodology and some pharmacies have been pressing for significant discounts. (Wall Street Journal)
Madlin Mekelburg was a reporting fellow for the Tribune in 2015 and 2016. She is a graduate of the University of Texas at Austin, where she studied journalism and French. Madlin previously worked at the... More by Madlin Mekelburg
